DOJ will provide updates to OMB regarding the implementation of SENTRY. Specifically, it will report on the effectiveness of the program to mitigate the impact of synthetic drugs in the US.
Going forward, DOJ will also provide detailed information on who is using the information, and what they are using it for.
Inventory as of this Action
Requested
Previously Approved
10/31/2010
36 Months From Approved
300
0
0
75
0
0
0
0
0
SENTRY/Emerging Drug Tracking System is an internet-based collection and dissemination system designed to help identify new syntetic drug-related behaviors at an early stage, evaluate their importance, and track their development. The ultimate goal of SENTRY is to inform and alert the counterdrug community to address problems at an early stage.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.